Last Price$395.5(0.3%)
Market Cap$90.7B
DCF value
$1,618.1
Undervalued (DCF value)
309.1%
Discount Rate
8.2%
Long-Term Growth Rate
3.0%
Stock quality
7/10
Good
ELV DCF Model
Free Cash Flow to Firm Model
NOPAT Model
Free Cash Flow to Equity Model
Net Income Model
Millions
Billions
| Dec'20 Actual | Dec'21 Actual | Dec'22 Actual | Dec'23 Actual | Dec'24 Actual | Dec'25 Estimate | Dec'26 Estimate | Dec'27 Estimate | Dec'28 Estimate | Dec'29 Estimate | Dec'30 Estimate | Dec'31 Estimate | Dec'32 Estimate | Dec'33 Estimate | Dec'34 Estimate | Dec'35 Terminal | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 121,867.0 16.9% | 138,639.0 13.8% | 156,595.0 13.0% | 171,340.0 9.4% | 176,810.0 3.2% | 189,124.3 7.0% | 203,231.9 7.5% | 225,584.7 11.0% | 319,438.8 41.6% | 434,723.7 36.1% | 567,639.8 30.6% | 709,889.6 25.1% | 848,636.9 19.5% | 967,700.2 14.0% | 1,050,099.5 8.5% | 1,081,602.5 3.0% |
% margin | 7,711.0 6.3% | 8,946.0 6.5% | 8,451.0 5.4% | 8,745.0 78.2% | 137,236.0 77.6% | 9,877.2 5.2% | 10,614.0 5.2% | 11,781.4 5.2% | 16,683.0 5.2% | 22,703.9 5.2% | 29,645.6 5.2% | 37,074.8 5.2% | 44,321.0 5.2% | 50,539.2 5.2% | 54,842.6 5.2% | 56,487.9 5.2% |
NOPAT % effective tax rate | 5,651.6 4.6% | 6,880.2 5.0% | 6,547.3 4.2% | 6,790.8 4.0% | 103,673.6 58.6% | 7,461.7 3.9% | 8,018.3 3.9% | 8,900.2 3.9% | 12,603.0 3.9% | 17,151.5 3.9% | 22,395.5 3.9% | 28,007.8 3.9% | 33,481.9 3.9% | 38,179.4 3.9% | 41,430.3 3.9% | 42,673.2 3.9% |
% of revenue | 1,154.0 0.9% | 1,302.0 0.9% | 1,675.0 1.1% | 1,745.0 1.0% | 0.0 0.0% | 1,316.4 0.7% | 1,414.5 0.7% | 1,570.1 0.7% | 2,223.4 0.7% | 3,025.8 0.7% | 3,950.9 0.7% | 4,941.0 0.7% | 5,906.7 0.7% | 6,735.5 0.7% | 7,309.0 0.7% | 7,528.2 0.7% |
% of revenue | (1,021.0) (0.8%) | (1,087.0) (0.8%) | (1,152.0) (0.7%) | (1,296.0) (0.8%) | (1,256.0) (0.7%) | (1,388.4) (0.7%) | (1,492.0) (0.7%) | (1,656.1) (0.7%) | (2,345.1) (0.7%) | (3,191.5) (0.7%) | (4,167.3) (0.7%) | (5,211.6) (0.7%) | (6,230.2) (0.7%) | (7,104.3) (0.7%) | (7,709.2) (0.7%) | (7,940.5) (0.7%) |
% of revenue | 5,203.0 4.3% | 784.0 0.6% | 253.0 0.2% | (535.0) (0.3%) | (1,719.0) (1.0%) | (707.9) (0.4%) | (760.7) (0.4%) | (844.4) (0.4%) | (1,195.7) (0.4%) | (1,627.2) (0.4%) | (2,124.7) (0.4%) | (2,657.1) (0.4%) | (3,176.5) (0.4%) | (3,622.1) (0.4%) | (3,930.6) (0.4%) | (4,048.5) (0.4%) |
Free Cash Flow to Firm (FCFF) % of revenue | 10,987.6 9.0% | 7,879.2 5.7% | 7,323.3 4.7% | 103,939.2 60.7% | 100,698.6 57.0% | 6,681.7 3.5% | 7,180.1 3.5% | 7,969.8 3.5% | 11,285.6 3.5% | 15,358.6 3.5% | 20,054.5 3.5% | 25,080.1 3.5% | 29,982.0 3.5% | 34,188.4 3.5% | 37,099.6 3.5% | 38,212.5 3.5% |
% of FCFF used in calculation | 83.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||||||
Discount period | 0.50 | 1.50 | 2.50 | 3.50 | 4.50 | 5.50 | 6.50 | 7.50 | 8.50 | 9.50 | ||||||
Discount factor | 0.96 | 0.89 | 0.82 | 0.76 | 0.70 | 0.65 | 0.60 | 0.56 | 0.51 | 0.47 | ||||||
Discounted FCFF (DFCFF) | 5,333.4 | 6,383.2 | 6,550.9 | 8,576.7 | 10,791.6 | 13,028.2 | 15,064.1 | 16,650.0 | 17,554.0 | 17,611.9 |
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
ELV DCF Value
DCF Value Calculation
as of Mar 03, 2025
Sum of DFCFF
% share of EV
117.5B
30.0%
Terminal Value (TV)
577.8B
Discounted TV
% share of EV
274.3B
70.0%
391.8B
8,288.0M
Total Debt
29.2B
370.9B
Shares outstanding
229.2M
FX rate
1.0
1,618.1
309.1% undervalued
Equity Value Bridge
ELV DCF Financials
Revenue
$176.8B -> $1,050.1B
19.5% CAGR
Operating Income
$137.2B -> $54.8B
(8.8%) CAGR
FCFF
$100.7B -> $37.1B
(9.5%) CAGR
ELV DCF sensitivity
DCF value
Long-term Terminal growth rate
2.0%
2.5%
3.0%
3.5%
4.0%
WACC
7.0%
$1,735.0
$1,735.0
$1,735.0
$1,735.0
$1,735.0
7.5%
$1,683.0
$1,683.0
$1,683.0
$1,683.0
$1,683.0
8.2%
$1,618.0
$1,618.0
$1,618.0
$1,618.0
$1,618.0
8.5%
$1,586.0
$1,586.0
$1,586.0
$1,586.0
$1,586.0
9.0%
$1,448.0
$1,529.0
$1,539.0
$1,539.0
$1,539.0
DCF value, undervalued / overvalued
Long-term Terminal growth rate
2.0%
2.5%
3.0%
3.5%
4.0%
WACC
7.0%
339.0%
339.0%
339.0%
339.0%
339.0%
7.5%
326.0%
326.0%
326.0%
326.0%
326.0%
8.2%
309.0%
309.0%
309.0%
309.0%
309.0%
8.5%
301.0%
301.0%
301.0%
301.0%
301.0%
9.0%
266.0%
287.0%
289.0%
289.0%
289.0%
Explore more intrinsic value tools hub for ELV
Margin of safety
Peter Lynch charts
Ben Graham Fair Value
Earnings Power Value
Relative Value
Earnings growth model
Discount rate
Peter Lynch Fair Value
Intrinsic Value
Reverse DCF
FAQ
What is Elevance Health Inc. DCF (discounted cash flow) valuation?
As of Mar 03, 2025, Elevance Health Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $1,618.1. This suggests it may be undervalued by 309.1% compared to its current price of around $395.5, using a WACC of 8.2% and growth rates of 3.0%.
What is Elevance Health Inc. WACC?
As of Mar 03, 2025, Elevance Health Inc.'s Weighted Average Cost of Capital (WACC) is approximately 8.2%.
What is Elevance Health Inc. Enterprise Value?
As of Mar 03, 2025, Elevance Health Inc.'s Enterprise Value (EV) is approximately $391.8B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.